Inari Medical, Inc. (NASDAQ:NARI) Q3 2024 Earnings Conference Call October 28, 2024 4:30 PM ET
Company Participants
Marissa Bych – VP, IR
Drew Hykes – President and CEO
Kevin Strange – CFO
Tom Tu – Chief Medical Officer
Conference Call Participants
Kallum Titchmarsh – Morgan Stanley
Marie Thibault – BTIG
David Rescott – Baird
Chris Pasquale – Nephron Research
Stephanie Piazzola – Bank of America
Lei Huang – Wells Fargo
Zachary Day – Canaccord Genuity
Michael Sarcone – Jefferies
Ravi Misra – Truist Securities
Matthew Blackman – Stifel
Operator
Good day, and welcome to the Inari Medical Third Quarter 2024 Earnings Call. [Operator Instructions] Also, please be aware that today’s call is being recorded.
I would now like to turn the call over to Marissa Bych, Vice President, Investor Relations. Please go ahead.
Marissa Bych
Thank you, operator, and welcome to Inari conference call to discuss our third quarter 2024 financial performance. Joining me on today’s call are Drew Hykes, President and Chief Executive Officer; and Kevin Strange, Chief Financial Officer.
This call includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements made on this call that do not relate to matters of historical fact should be considered forward-looking statements, including statements related to Inari’s estimated full year 2024 revenue, operating loss or profitability expectations and the expected operating performance and potential strategic benefits of LimFlow. These statements are based on Inari’s current expectations, forecasts and assumptions, which are subject to inherent uncertainties, risks and assumptions that are difficult to predict.
Actual outcomes and results could differ materially from any results, performance or achievements expressed or implied by the forward-looking statements due to several factors. Please review Inari’s most recent filings with the SEC particularly the risk factors described in our latest Form 10-K for
